Treatment with inebilizumab was associated with continued improvement in patients with AChR+ generalized myasthenia gravis, according to 52-week results from the MINT trial.
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
MedPage Today on MSN1d
Myasthenia Gravis Antibody TypesMyasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
Clinical Trials Arena on MSN5d
Amgen’s gMG therapy cuts disease symptoms at one-year markResults from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...
Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 278.69 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback